Category Archives: Business and Investments

Latest From Business and Investments

BIO Letter of Support for 21st Century Cures Legislation

21st Century Cures Act

Today, BIO sent a letter to Reps. Boehner and Pelosi in support of the 21st Century Cures Act. In the letter, we applaud Chairman Upton, Ranking Member Pallone and Congresswoman DeGette’s efforts on H.R. 6., which takes important steps toward placing patients at the center of the drug development process. We also expressed support for precision medicine through genomics and regulatory science to help better understand the molecular basis of disease and develop precision therapies tailored to each Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Bio Report: What a Decade of Investment Tells Us About the Health of Biotech

Emerging Therapeutic Company Investment and Deal Trends

In this podcast, The Bio Report’s Daniel Levine interviews BIO’s Dave Thomas on the recent release of a new BIO Industry Analysis report – Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2005-2014) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers a first-time look at the degree of collaboration across the industry’s clinical pipeline. Some of the key findings Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?

72263479

In many ways, 2014 was a record year for biopharma dealmaking, with $355 billion in total transactions, including $53 billion in partnering deals, $16.5 billion in venture investments and 133 IPOs. According to the 2015 Campbell Alliance Dealmakers’ Intentions Study, 2015 is shaping up to be the year of historic M&A in the biopharmaceutical sector, driven in part by greater access to capital. The partnering numbers at BIO 2015 further indicate that the appetite for Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Complexities of Rare Diseases Take the Spotlight at BIO

Orphan Drugs

Global Genes Founder & CEO Nicole Boice opened the BIO 2015 Orphan & Rare Disease Track by addressing a packed session with a simple, powerful statement: “We’re all working to eliminate the challenges of rare diseases, but patients and their advocates aren’t always equipped to fight.” Organizations like Global Genes help families affected by rare disease by connecting them with much needed tools and resources. By better understanding the definition of a “rare” disease, industry Read More >

Business and Investments, Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Legislative Best Practices in Support of Bioscience Economic Development

shutterstock_26191726

Despite a difficult economic environment the past couple years, states across the country have found that a number of factors are key to attracting new bioscience industry and helping current bioscience companies thrive in their states. In particular, state initiatives that focus on capital formation, workforce development and a supportive business environment have been key to the success of states that want to grow their bioscience industry In a session titled “Legislative Best Practices in Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,